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INTRODUCTION
Distant metastatic disease from esophageal cancer is subclas-
sified as M1a (distant, nonregional lymph node metastases)
or M1b (other distant metastases). M1a disease is further clas-
sified by tumor location; M1a tumors of the upper thoracic
esophagus metastatic to cervical nodes and M1a tumors of
the lower thoracic esophagus metastatic to celiac lymph nodes.
M1b tumors represent other distant metastases, namely, upper
thoracic esophagus metastatic to noncervical nonregional
lymph nodes or other distant sites, mid thoracic esophagus
metastatic to either nonregional lymph nodes or other distant
sites, and lower thoracic esophagus metastatic to nonceliac
nonregional lymph nodes or other distant sites. Some reports
have concerned the prognosis of M1a and M1b after the sur-
gical resection of esophageal carcinoma. We report our sur-
gical results of M1a and M1b esophageal squamous cell car-
cinoma and evaluate the clinical relevance of the M1a and
M1b subclassification.
MATERIALS AND METHODS
We reviewed the data of the patients who had pathological
M1a or M1b disease after esophageal resection and lymph
node dissection. Fifty-six patients underwent esophageal resec-
tion and lymph node dissection from November 1994 to De-
cember 2001, composed of 4 transhiatal resections, 33 Ivor
Lewis procedures, and 19 three-stage procedures, which includ-
ed cervical anastomosis and node dissection. Operative mor-
tality, including in-hospital deaths, occurred in 3 patients
(5.4%). They had all undergone three-field lymph node dis-
section. Two patients died of respiratory failure and one pati-
ent died of sepsis. The remaining 53 patients were discharged,
and their primary tumor sites were as follows; 10 upper, 23
middle, and 20 lower thoracic esophagus. The histologic type
was squamous cell carcinoma in all patients, and all were
found to have M1 disease by pathologic examination of the
dissected lymph nodes, 24 M1a and 29 M1b (Table 1). Of the
29 M1b patients, three patients had intraoperative findings
of pleural, hepatic, and satellite gastric metastasis respectively.
The other 26 patients had metastases to the nonregional lymph
nodes. Forty-two patients (79%) were considered to have
undergone curative resection according to a tumor-negative
resection margin. Chemotherapy and/or radiation therapy was
given to 38 patients preoperatively or postoperatively. Recur-
rences and survivals were calculated for patients who were
discharged. Survival was compared using the log rank test,
Young Mog Shim, Yong Soo Choi,
Kwhanmien Kim
Department of Thoracic and Cardiovascular Surgery,
Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Korea
Address for correspondence
Young Mog Shim, M.D.
Department of Thoracic and Cardiovascular Surgery,
Samsung Medical Center, Sungkyunkwan University
School of Medicine, 50 Irwon-dong, Gangnam-gu,
Seoul 135-710, Korea 
Tel : +82.2-3410-3482, Fax : +82.2-3410-0089
E-mail : ymshim@smc.samsung.co.kr
229
J Korean Med Sci 2005; 20: 229-31
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Prognosis After Surgical Resection of M1a/M1b Esophageal 
Squamous Cell Carcinoma
This study was undertaken to examine prognosis after resection for M1 disease in
squamous cell esophageal carcinoma. Fifty-six patients with M1 esophageal cancer
underwent esophageal resection with two or three-field nodal dissection from 1994
to 2001. Operative mortality occurred in 3 patients. Primary tumor sites were as fol-
lows; 10 upper, 23 middle, and 20 lower thoracic esophagus. They were found to
have M1 disease by pathologic examination of dissected nodes, 24 M1a and 29
M1b. Forty-two patients (79%) were considered to have undergone curative resec-
tion. Chemotherapy and/or radiation therapy was given to 38 patients perioperatively.
Recurrence was identified in 35 patients (66%) during a mean follow-up of 23 months.
Overall median and 5-yr survivals were 19 months and 12.7%. Five-year survivals
for M1a and M1b disease were 23.9% and 6.1%, respectively (p=0.0488). Curative
resection tended to show better survival (p=0.3846). Chemotherapy and/or radia-
tion therapy provided no advantage (p=0.5370). Multivariate analysis showed that
M1b was significant risk factor over M1a disease. Our conclusion is that surgical
resection can provide acceptable survival in thoracic squamous esophageal cancer
with M1a disease. Survival differences between M1a and M1b disease support the
current subclassification staging system.
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and the Cox regression test was used for univariate and multi-
variate analyses by using SPSS (ver. 10.0).
RESULTS
Recurrence was identified in 35 patients (66% of 53 pati-
ents) during follow-up for a mean 23 and a median 15.4 mon-
ths (3 to 80 months). Locoregional recurrences were detected
in 19, visceral distant metastases in 7, and locoregional recur-
rences with distant metastases in 9 (Table 2). When simulta-
neous locoregional recurrences and distant metastases were
considered as distant relapse, locoregional relapse was more
common in M1a than in M1b, but without statistical differ-
ence (p=0.123).
Overall median survival, 3-, and 5-yr survivals were 19 mon-
ths, 25.1%, and 12.7% (Fig. 1). Three-, and 5-yr survivals of
M1a and M1b were 35.8%, 23.9% and 16.3%, 6.1%, respec-
tively. Patients with M1a disease showed better survival than
those with M1b disease by the log rank test (p=0.0488) as
shown in Fig. 2. Well differentiated tumors showed better
survivals than poorly differentiated tumors (p=0.0428). Cura-
tive resection showed better survival than incomplete resec-
tion but this lacked statistical significance (p=0.3846). Adju-
vant chemotherapy and/or radiation therapy provided no ad-
vantage (p=0.5370). Clinical stage and type of operation had
no effect according to the survival curve.
Univariate correlates of survival by Cox regression were
analyzed in Table 3. Patients with poor differentiation and
M1b disease had a higher risk than those with well differen-
tiated M1a disease. Multivariate analysis was performed using
likelihood-ratio statistics based on the conditional parameter
estimate, and M1b disease was found to be the only signifi-
cant risk factor in the prognosis of stage IV esophageal squa-
mous cell carcinoma.
DISCUSSION
Involvement of the more distant lymph nodes (for example,
the cervical or celiac nodes for intrathoracic tumors) is consid-
ered distant metastasis in the sixth edition of the American
Variable
All patients 
(% of 53)
M1a
(% of 24)
M1b
(% of 29)
p
Male Sex 52 (98) 24 (100) 28 (97) 1.000
EUS 30 (57) 17 (71) 13 (45) 0.057
PET 26 (49) 11 (46) 15 (52) 0.669
Tumor location 0.000
Upper 10 (19) 9 (38) 1 (3)
Middle 23 (43) 0 (0) 23 (79)
Lower 20 (38) 15 (62) 5 (17)
Differentiation 0.274
Poor 12 (23) 3 (13) 9 (31)
Moderate 29 (54) 15 (63) 14 (48)
Well 12 (23) 6 (25) 6 (21)
Preop. stage 0.649
IIA 4 (8) 1 (4) 3 (10)
IIB 1 (2) 0 (0) 1 (3)
III 38 (72) 18 (75) 20 (69)
IV 10 (19) 5 (21) 5 (17)
Type of operation 0.070
Ivor Lewis procedure 33 (62) 13 (54) 20 (69)
Right thoracotomy and  16 (30) 7 (29) 9 (31)
neck and abdominal 
incisions
Transhiatal resection 4 (8) 4 (17) 0 (0)
Resection margin 0.195
Negative 42 (80) 21 (88) 21 (72)
Microscopically positive 5 (9) 1 (4) 4 (14)
Grossly positive 6 (11) 2 (8) 4 (14)
Preoperative treatment 0.877
RTx. 2 (4) 1 (4) 1 (3)
CTx. 4 (8) 2 (8) 2 (7)
RTx. and CTx. 3 (6) 2 (8) 1 (3)
None 44 (83) 19 (79) 25 (86)
Adjuvant therapy 0.866
RTx. 7 (13) 4 (17) 3 (10)
CTx. 24 (45) 10 (42) 14 (48)
RTx. and CTx. 3 (6) 1 (4) 2 (7)
None 19 (36) 9 (38) 10 (34)
Table 1. Clinical characteristics of 53 patients with squamous
esophageal carcinoma
EUS, esophageal ultrasound; PET, positron emission tomography; RTx.,
radiotherapy; CTx., chemotherapy.
Site of relapse M1a M1b Total patients
Locoregional 12 7 19
Locoregional and distant 3 6 9
Distant 2 5 7
Total 17 18 35
Table 2. Initial site of relapse in M1a or M1b disease
Variable Odds ratio 95% CI p
Differentiation
Moderate/well 2.15 0.87-5.28 0.096
Poor/well 3.05 1.11-8.37 0.031
Clinical stage
III/II 0.84 0.29-2.43 0.746
IV/II 1.12 0.34-3.74 0.855
Type of operation
three-field /I-L 1.18 0.36-3.92 0.787
transhiatal /I-L 1.14 0.32-4.06 0.840
Resection margin
Positive/negative 1.39 0.64-3.01 0.411
Adjuvant therapy
Done/none 1.23 0.64-2.37 0.539
M1a or M1b
M1b/M1a 1.87 0.99-3.58 0.053
Table 3. Univariate correlates of survival 53 patients with squa-
mous esophageal carcinoma
CI, confidence interval; I-L, Ivor Lewis procedure.Prognosis of M1 Esophageal Cancer 231
Joint Committee on Cancer (AJCC) current staging (1). Pre-
vious reports suggested that nonregional metastases are resec-
table and that they are associated with a better survival than
visceral metastases after surgical resection (2, 3). A recent report
pointed out that the N1 versus M1a versus M1b descriptors
do not accurately identify prognostically different groups (4).
Christie and colleagues concluded that although there are
statistically significant survival differences between M1a and
M1b diseases, these differences are not clinically important
due to a survival of less than 10% in both diseases (5). Their
experiences mainly included adenocarcinoma of the distal
thoracic esophagus and of the esophagogastric junction. Our
data concerns only esophageal squamous cell carcinoma because
of epidemiological characteristics in East Asian countries. It
is not yet clear if the two cell types differ biologically or merely
in location (6).
Operative results showed an acceptable range of operative
and in-hospital mortality, but 81% of our patients were clin-
ically stage II or III. We obtained an overall survival compa-
rable to that of previous report (2). M1a disease showed better
survival than M1b and this had clinical and statistical signifi-
cance, which support the suggestion that the involvement of
cervical or celiac nodes by intrathoracic tumors be classified
as N2 disease rather than M1a. Ide and associates in Japan
considered metastases from lower thoracic esophageal carci-
nomas to the celiac nodes as N2 rather than Ml disease (7).
Such a change in classification requires further study. More-
over, our data would benefit from longer follow-up period.
Our results indicate that preoperative nodal staging is im-
portant because M1b disease has poor results after surgical
resection. Preoperative accurate assessment of lymph nodes
can be achieved by techniques like EUS-guided needle biop-
sies and PET. If lymph nodes are found to be positive, then
whether the patients should be administered neoadjuvant
therapy is another issue for study. Adjuvant chemotherapy
and radiotherapy may or may not offer a survival advantage
in patients with advanced esophageal cancer. Our data showed
no advantage from adjuvant therapy, but this is not conclusive
because of the heterogeneity and the small number of patients.
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Fig. 1. Overall survival in 53 patients.
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Fig. 2. Survival in patients with M1a or M1b disease. Three-year
and 5-yr survivals for those with M1a were 35.8% and 23.9%.